QUESTION
What is the difference between phenotypic versus genotypic resistance?
ANSWER
The rise of antimicrobial resistance (AMR) presents a significant challenge to public health. As bacteria develop mechanisms to evade the effects of antibiotics, selecting the most appropriate antimicrobial involves less options. As antimicrobial susceptibility testing and rapid molecular diagnostics evolve, two key concepts for clinicians are crucial for understanding AMR: genotypic and phenotypic resistance. These are not mutually exclusive terms. Despite often inappropriate substitution of the two terms, these two concepts are not interchangeable.
Genotypic resistance refers to the presence of specific genetic targets within an organism’s genome. These targets can take various forms, including mutations in genes encoding essential targets for antibiotics or the acquisition of genes encoding enzymes that can degrade or inactivate antibiotics such as CTX-M-15 or ampC. Essentially, genotypic resistance equips bacteria with the genetic machinery to resist certain antibiotics.
Phenotypic resistance, on the other hand, describes the observable resistance of a bacterial population to an antibiotic. It’s determined through clinical microbiology laboratory tests, such as minimum inhibitory concentration (MIC) assays, which measure the lowest concentration of an antibiotic required to inhibit bacterial growth. A bacterium with phenotypic resistance demonstrates a measurable ability to survive or continue multiplying despite the presence of an antibiotic.
The Key Distinction:
The critical difference lies in what each concept reveals. Genotypic testing identifies the genetic potential for resistance, regardless of whether the resistance translates to a survival advantage in the presence of the antibiotic. Phenotypic testing, conversely, directly assesses the functional ability of a bacterial population to resist the antimicrobial’s effects.
However, phenotypic testing remains the cornerstone for determining appropriate antibiotic therapy. Not all bacteria with genotypic resistance will necessarily exhibit phenotypic resistance. Factors like the specific mutations present, the overall genetic makeup of the bacteria, and environmental factors can all influence the expression of resistance. Additionally, many mechanisms of resistance are not detectable with the most widely available rapid molecular diagnostics.
A commonly taught example of the importance of harmonized genotypic and phenotypic resistance is navigating the treatment of clinically significant ampC β-lactamase producing Enterobacterales. While an Enterobacter aerogenes isolated from the blood might display a phenotype on the susceptibility report suggesting ceftriaxone is an appropriate antimicrobial, knowledge about the genotype of Enterobacter aerogenes’s clinically significant likelihood of becoming resistant to ceftriaxone due to increase ampC production following induction with certain antibiotics, like ceftriaxone.
In conclusion, genotypic and phenotypic resistance represent two sides of the AMR coin. Genotypic information unveils the inherent resistance potential, while phenotypic information displays the functional resistance displayed by organisms. Both types of testing play a vital role in selecting the right antimicrobial, at the right dose, for the right duration in the right patient.
READINGS
- The Genotype-to-Phenotype Dilemma: How Should Laboratories Approach Discordant Susceptibility Results?
- Update on Susceptibility Testing: Genotypic and Phenotypic Methods
- Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists
- Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates
- Clinical Use of Genotypic and Phenotypic Drug Resistance Testing to Monitor Antiretroviral Chemotherapy
- Discrepancies between phenotypic and genotypic identification methods of antibiotic resistant genes harboring Staphylococcus aureus
- Establishing Genotype-to-Phenotype Relationships in Bacteria Causing Hospital-Acquired Pneumonia: A Prelude to the Application of Clinical Metagenomics
ANSWERED BY
Hunter O. Rondeau, Pharm.D., BCIDP with assistance from Google Gemini AI – September 2024
Q&A DISCLAIMER
The ID PharmD Q&A pages attempt to answer common pharmacy questions by providing the perspective and opinion of a trained expert with knowledge relevant to the question. That noted, these answers are not provided as all-inclusive comprehensive responses. This is not provided for direct patient care purposes.
RECOMMENDED TO YOU
